Molecular Mechanisms of Semaglutide and Liraglutide as a Therapeutic Option for Obesity (April 2024) Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation (May 17, 2025) FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes (December 23, 2024) FDA Approves Weight Management Drug for Patients Aged 12 and Older (June 15, 2021) Victoza (liraglutide) Injection, for Subcutaneous Use
$299 Initial In-office Assessment $99 Initial Follow-Up Click here to see current discounts NOTE: $99 initial follow-up cost only applicable to the FIRST follow-up appointment
Although some studies report clear benefits, others show little to no improvement, and in some cases, even adverse effects
The absence of a gallbladder fundamentally alters bile storage and release, creating unique metabolic conditions that affect how GLP-1 receptor agonists work in your body
Research studies on topical application typically report measurable skin parameter changes between 4 and 12 weeks
